Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


"I like only having to use one product and being able to make it through my workweek without getting bleeds.” 
 

Being a woman with hemophilia

Throughout my childhood, I had a gut feeling that I was more than just a carrier because of how easily I bruised. For a long time, my family and doctors didn’t take me seriously when I was injured and told them I wasn’t healing properly. I basically raised myself to think proactively like a hemophiliac, but if I expressed my suspicions that I, too, had hemophilia, the notion was quickly dismissed because "women are only carriers"—or at least that’s what they thought. There were times growing up when I didn’t even say anything because I knew it wouldn’t be taken seriously, but in those moments, my symptoms did the screaming. I tried for years to get a hemophilia diagnosis without success, until I made an appointment with a hematologist who is also a woman with hemophilia.
 

Getting treatment that works for me

After being diagnosed, my prophylaxis regimen wasn’t working for me, so I switched from infusing factor twice weekly to doing subcutaneous injections twice monthly, supplementing with factor for breakthrough bleeds—and I had muscle bleeds in my legs regularly. I knew it was time to switch again when, at age 39, I needed a knee replacement. My hematologist told me about ALTUVIIIO, which my brother Chris I was also taking for hemophilia A. After talking with my doctor about it, I made the switch. It was a simple transition for me.
 

Life with ALTUVIIIO

The ease of once-weekly treatment with ALTUVIIIO is very different than infusing factor 2 to 3 times weekly. It gives me more freedom to focus on the things I enjoy doing, like nature walks, hiking, yoga, and working with the hemophilia community. My hope is that with each conversation and presentation, we take a step toward a world where women with hemophilia, and all people with hemophilia, are diagnosed quickly and given the treatment they need.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Chrissy is a promotional speaker compensated by Sanofi.

Discover More Patient Experiences

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2508205-v1.0-11/2025 Last Updated: November 2025